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THE EFFECT OF PROTEIN KINASE C AND BETA-CATENIN INHIBITORS 
ON UVEAL MELANOMA CELLS  
ASHA GOWDA 
ABSTRACT 
Purpose: Uveal melanoma (UM) is the most common intraocular malignancy in adults 
with an incidence of six per one million individuals each year. Globe conserving 
treatments are currently the standard of care, but unfortunately, despite successful local 
control, a substantial mortality risk exists due to eventual emergence of distant 
metastasis, which is invariably lethal. There is therefore an unmet need for novel, 
effective, targeted therapies for metastatic UM. Somatic mutations in the G-protein α 
subunits, Gαq and Gα11, are present in a mutually exclusive pattern in approximately 
80% of UMs, and they abolish the GTPase activity, resulting in a constitutively active 
protein. We have previously demonstrated that GNAQ-mutant (GNAQmt) UMs are 
addicted to the oncogenic effect of the mutant GNAQ protein and dissected the GNAQ 
pathway in an attempt to identify druggable targets. Our findings that the mutant GNAQ 
protein activates the PKC/PKD axis, which activates beta-catenin (ß-Catenin), prompted 
us to investigate the role of PKC and ß-Catenin in GNAQmt UM. 
Experimental Design: The GNAQmt UM cell lines Mel202 and OMM1.3 were treated 
with either the PKC inhibitor bisindolylmaleimide I (BIM) alone, the Wnt/ß-Catenin 
inhibitors FH535 or cardamonin alone, the Wnt/ß-Catenin activator Wnt-3a alone, or 
siRNAs for ß-Catenin in combination with BIM, and their viability was assessed with the 
MTT assay. Levels of β-Catenin, phosphorylated AKT, ERK1/2, caspase 3 and LC3BII 
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were assessed with western blotting. β-Catenin mRNA levels were assessed with 
microarray analysis and RT-PCR. 
Results: GNAQmt UM cells are very sensitive to PKC inhibition and respond with a 
decrease in cell viability that involves autophagy and cleavage and translocation of 
LC3BII in autophagosomes, but not caspase activation. PKC inhibition results in the 
upregulation of ß-Catenin protein, but not mRNA levels, through a post-translational 
mechanism that involved the phosphorylation and activation of AKT, but not ERK1/2. β-
Catenin inhibition by either small molecule inhibitors or siRNA resulted in a dose-
dependent increase of cell proliferation, whereas ß-Catenin activation by Wnt-3a had the 
opposite effects, resulting in a decrease in cell viability.   
Conclusions: Our study demonstrates that PKC is a mediator of the oncogenic effect of 
mutant Gα protein in UM through the Wnt-3/ß-Catenin signaling pathway. These results 
open exciting opportunities for the development of personalized targeted therapies for 
UM in a genotype-dependent fashion. 
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INTRODUCTION 
 
  Uveal melanoma (UM) is the most common primary malignancy of the eye that 
arises from melanocytes in the uveal tract, consisting of the iris, ciliary body, and choroid 
(Ocular Melanoma 2014). UM represents less than five percent of all melanomas and 
affects roughly six in every one million people, yearly (Buder et al. 2013). In most cases, 
UM does not present with any symptoms and requires an eye examination to be detected 
(Marshall et al. 2013). Although in the past enucleation was the primary treatment, this 
mode is currently suitable only for large tumors, eyes without useful vision, pain, or 
patients that are at risk of not being compliant with follow up. In the last several decades, 
the treatment of UM has shifted to globe conserving therapies that are currently the 
standard of care; these include radiotherapy with charged particles (proton beam therapy) 
or radioactive iodine (brachytherapy), photocoagulation, transpupillary thermotherapy, 
and rarely, local resection (Gragoudas 2006). Unfortunately, despite successful local 
treatment and control, a substantial mortality risk exists due to eventual emergence of 
distant metastasis that occur in almost 50% of all cases (Marshall et al. 2013; Spagnolo et 
al. 2012). This is postulated to be due to early micrometastasis and hematogenous 
dissemination of tumor cells (Balch et al. 2001). 
 According to the largest controlled study of UM, the Collaborative Ocular 
Melanoma Study (COMS), the all-cause mortality for successfully treated large ocular 
melanomas is close to 50%, whereas for medium-sized ones is 30% (Collaborative 
Ocular Melanoma Study Group 2001; Collaborative Ocular Melanoma Study Group 
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2006). Once the disease hematogenously spreads beyond the eye, prognosis is poor, with 
only 13% of patients surviving more than 1 year, and the median survival time after 
diagnosis of distant metastasis is only five to seven months despite systemic treatment 
(Gragoudas et al. 1991; Bedikian 1995; Pons et al. 2011). Survival time for UM patients 
is dependent on the location of metastasis; about 90% of UM cases metastasize to the 
liver, after which the median survival time decreases to four to five months (Spagnolo et 
al. 2012). Even when metastatic disease is discovered early in asymptomatic patients, 
treatment does not improve overall survival (Rietschel et al. 2005). Therefore, a systemic 
agent that could be used in conjunction with globe-sparing modalities that eradicate or 
prevent the micrometastatic disease is an attractive option for the adjuvant treatment of 
primary UM. Available systemic treatments provide negligible benefit and as we have 
previously shown, revolutionary treatments that are beneficial for metastatic cutaneous 
melanomas do not show promising results on metastatic UM (Mitsiades et al. 2011). 
Therefore, there is an unmet need for novel, effective targeted therapies for metastatic 
UM. Several pathways have been identified as important players in the pathogenesis of 
UM that are involved in cell growth, migration survival and apoptosis (Miyamoto et al. 
2012). Such pathways include the mitogen-activated protein kinase (MAPK)/ERK, 
phosphatidylinositol 3-kinase (PI3K)/AKT, Wnt/ß-Catenin, and GNAQmt pathways, and 
offer potential candidates for targeted and personalized therapy.  
 
Guanine Nucleotide-Binding Proteins 
 Guanine nucleotide-binding proteins are a family of heterotrimeric proteins 
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composed of α, β and γ subunits that couple cell surface seven-transmembrane domain 
receptors, such as G protein-coupled receptors (GPRCs), to intracellular signaling 
pathways (Johnston and Siderovski 2007). The GPRCs form the largest known family of 
cell surface receptors (1% of the human genome) and mediate cellular responses to a 
diverse array of signaling ligands (Strathmann and Simon 1990; Breitwieser 2004). 
GPRCs and their ligands are overexpressed in various malignancies and contribute to 
cancer cell growth and survival via autocrine growth loops (Rozengurt 2002). GPRC 
activation catalyzes the exchange of guanosine triphosphate (GTP) for guanosine 
diphosphate (GDP) bound to the inactive G protein α subunit, resulting in a 
conformational change and dissociation of the β-γ subunits from the complex (Van 
Raamsdonk et al. 2008). The G protein α, β and γ subunits that belong in the Gαq family 
of G protein α subunits are ubiquitously expressed in tissues, and upon activation they 
stimulate phospholipase C-beta (PLCβ) (Gaudi and Messina 2011). Gα signaling is 
normally terminated by a GTPase intrinsic to the Gα subunit (Gaudi and Messina 2011). 
PLCβ catalyzes the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) to produce 
two second messengers: inositol 1,4,5-triphosphate (IP3), which triggers the release of 
Ca2+ from internal stores, and diacylglycerol (DAG), which elicits cellular responses 
through a variety of effectors including protein kinase C (PKC) and MAPK (Gaudi and 
Messina 2011; Patel et al. 2011). The PKC family consists of several isozymes that 
exhibit differential expression patterns, subcellular localization, and responsiveness to 
extra-cellular signals that are thought to explain their distinct and unique functions in the 
cell (Dekker and Parker 1994). Specific isotypes of PKCs are reported to be 
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overexpressed in various carcinomas, suggesting their importance as players in cancer 
pathophysiology (Donson et al. 2000; Eder et al. 2005). Through	  a	  cascade	  of	  events,	  GTP-­‐bound	  Gα	  subunits	  ultimately	  influence	  cellular	  properties	  and	  activities,	  including	  cell	  growth	  and	  differentiation	  (Spagnolo	  et	  al.	  2012;	  Van	  Raamsdonk	  et	  al.	  2008).	   
 
Figure 1: GNAQ/GNA11-Stimulated Activation of PKC and MAPK/ERK Signaling 
Pathway. GNAQ and GNA11 mutations cause aberrant signaling, initiated by GTP-
bound Gα subunit. Upon activation, its downstream target, PKC, can proceed to stimulate 
the MAPK/ERK pathway, which leads to tumor growth and proliferation.  
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Gα Protein Mutations in Uveal Melanoma 
 The GNAQ and GNA11 genes code for two Gα subunits, Gαq and Gα11, 
respectively, which are 88% homologous (Strathmann and Simon 1990). Somatic 
mutations in the heterotrimeric G protein α subunit genes GNAQ (40-50% of primary 
UMs) or its closely related GNA11 (30% of primary UM) represent an oncogenic effect 
in UM (Lamba et al. 2009; Onken et al. 2008). The most frequent mutations occur in 
codon Q209, where a glutamine residue is substituted with a different amino acid residue 
and affects the Ras-like domain, abolishing the intrinsic GTPase activity in a manner 
similar to the effect of the NRAS mutations found in cutaneous melanomas (Van 
Raamsdonk et al. 2008; Van Raamsdonk et al. 2010). These mutations result in a 
constitutively active protein that functions as a bona fide oncogene (Figure 1) and occur 
early in UM carcinogenesis, contrary to other genetic events that are associated with 
increased metastatic potential, such as the recently described BAP1 (BRCA1-associated 
protein 1) mutations (Van Raamsdonk et al. 2010; Harbour et al. 2010). Primary 
melanocytes that are transduced with mutant GNAQ or GNA11 form rapidly growing 
tumors in immunocompromised mice, which provides evidence, together with the high 
frequency of activating somatic mutations in GNAQ or GNA11 in UMs, for the crucial 
role of Gαq/Gα11 proteins in the development of UM (Van Raamsdonk et al. 2008). 
 Irregularity in the functions of these heterotrimeric G-protein α subunits has been 
considered pivotal in the development of malignant UM because mutant Gα subunits are 
capable of constitutively activating a number of downstream elements, including the 
MAPK/ERK pathway that is a dominant route for UM pathogenesis (Jovanovic et al. 
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2013; Khalili et al. 2012). Activation of this pathway is present in about 86% of primary 
UM tumors and correlates with mutated GNAQ and GNA11 genes in more than 80% of 
primary UM cases (Patel et al. 2011). More than half of all metastatic UM have 
mutations in the GNA11 gene, as opposed to the 22% of metastatic UM having GNAQ 
mutations; thus, GNAQ is suggested to play a greater role in the early stages of UM and 
GNA11 in the later stages of malignancy (Jovanovic et al. 2013). Taking into account the 
predominance of GNAQ mutations during the early development of UM, a better 
understanding of its behavior and expression may lead the way to successful treatment 
options for UM prior to its metastasis.  
 Mutations in the GNAQ gene are associated with nearly half of all UM cases 
(Jovanovic et al. 2013). The effects of aberrant GNAQ activity are similar to those of 
growth factors, as this oncogene is believed to contribute to melanocyte growth and 
transformation in mice (Onken et al. 2008). Our particular study examined the molecular 
pathways involved in two UM cell lines, MEL202 and OMM1.3. Although the MEL202 
line originates from primary UM and OMM1.3 stems from UM liver metastases, both of 
these cell lines carry mutations in GNAQ (Wu et al. 2012). The missense mutation in 
GNAQ leads to the substitution of glutamine at codon 209 with leucine in MEL202 cells 
and with proline in OMM1.3 cells (Wu et al. 2012). 
 
Protein Kinase C 
 The PKC family of serine/threonine kinases is involved in phosphorylating and 
regulating of a wide array of substrates that trigger diverse cellular reactions (Newton 
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1995; Wu et al. 2012). Conventional isoforms of PKC include α, βI, βII, and γ, and novel 
isoforms include δ, ε, θ, and η; both groups are activated by DAG and phospholipids, but 
only the former is dependent on intracellular calcium levels to influence their particular 
downstream targets (Wu et al. 2012). Each of these isoenzymes has disparate regulatory 
effects on cell behavior (Teicher 2006). For instance, PKCβI partakes in tumor 
progression, while PKCδ participates in tumor suppression (Teicher 2006). Aberrant 
activity of PKC can trigger the MAPK/ERK pathway and influence cell death, 
proliferation, and angiogenesis, to name a few (Figure 1) (Wu et al. 2012). This pathway 
is triggered when activated PKC signals the kinase MEK to phosphorylate ERK, which in 
its reactive form can accumulate in the nucleus to control gene transcription and 
expression (Patel et al. 2011). The phosphorylated form of ERK can have strong effects 
on cellular activity, as it is capable of upregulating the pathway’s constitutive activity by 
increasing the expression of specific extracellular receptor tyrosine kinase ligands that are 
responsible for initiating this cascade effect (Roberts & Der 2007). 
 
Protein Kinase C in Uveal Melanoma 
 Since a large portion of UM cases exhibit GNAQ mutations, PKC involvement in 
the development of UM tumors can be expected (Van Raamsdonk et al. 2008). Treatment 
of GNAQmt UM cell lines with PKC inhibitors prevents cell growth, and confirms that 
PKC is largely responsible for promoting cell proliferation in GNAQmt cells (Chen et al. 
2013). Although PKC’s oncogenic role in UM tumor progression has been established, it 
can activate a number of downstream targets, and so the exact method through which it 
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influences proliferation is not completely understood (Koivunen et al. 2006). In addition 
to PKC’s large impact on UM development, its ability to bind oncogenic phorbol esters 
makes it an attractive target for therapies, and so its behavior must be further investigated 
in UM progression (Teicher 2006). 
 
Wnt/ß-Catenin Signaling Pathway 
 The Wnt/ß-Catenin pathway (Figure 2) is a signal transduction pathway that 
relays messages to the interior of the cell upon binding of a secreted glycoprotein of the 
Wnt family to a seven-transmembrane domain receptor (MacDonald et al. 2009). 
Multifarious cellular responses can be triggered due to the many types of Wnt ligands and 
cell surface receptors that exist within a system (Miller et al. 1999). To date, there are 
three distinct Wnt signaling pathways: the canonical, or ß-Catenin-dependent, pathway, 
and the two non-canonical, planar cell polarity and Wnt/Ca2+, pathways (Komiya and 
Habas 2008). The canonical Wnt/ß-Catenin signal transduction pathway has been 
observed to be involved in many UM cases, and so it will be highlighted in this paper.  
 When the Wnt/ß-Catenin pathway is not activated, ß-Catenin is predominantly 
localized at the cell membrane, where it functions to mediate the adhesion between E-
cadherin in the plasma membrane and actin microfilaments of the cytoskeleton (Cadigan 
2008). If ß-Catenin is present in the cytoplasm, it is degraded by the APC-Axin-CKI-
GSK-3 protein complex (Cadigan 2008). Degradation is initiated when the APC-Axin 
tumor suppressing complex binds to ß-Catenin to allow for easy and accessible 
phosphorylation of serine 45 by CKI, and serine 33, serine 37 and threonine 41 by GSK-3 
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(Cadigan 2008; MacDonald et al. 2009). These modifications of ß-Catenin prompt poly-
ubiquitination, which marks the protein for complete degradation and prevents unwanted 
gene transcription (Cadigan 2008). Within the nucleus, the repressor TLE/Groucho (Gro) 
interacts with DNA-bound T-cell factor/Lymphoid enhancing factor (TCF/LEF) 
transcription factors and promotes their activity as transcriptional repressors of Wnt 
target genes (Logan & Nusse 2004).   
 When Wnt ligands bind Frizzled, contact between the GPCR and two lipoprotein 
receptor-related proteins (LRP), LRP5 and LRP6, are stimulated and the downstream 
cascade effects are initiated (Logan & Nusse 2004; Cadigan 2008). Upon pathway 
activation, ß-Catenin evades degradation and accumulates in the cytoplasm (Logan & 
Nusse 2004). The high concentration of ß-Catenin in the cytoplasm enables it to pass into 
the nucleus, bind the DNA-bound TCF/LEF transcription factors to release the 
repressors’ functions, and direct gene transcription (Logan & Nusse 2004; MacDonald et 
al. 2009; Miller et al. 1999; Staal and Clevers 2000). Wnt/ß-Catenin-dependent gene 
expression is capable of affecting cell proliferation and leading to cancer, and so strict 
regulation of the Wnt/ß-Catenin pathway is imperative (Logan & Nusse 2004). Mutations 
in molecules involved in major events such as the degradation of ß-Catenin or repression 
of transcription can lead to aberrant activation of the pathway (Logan & Nusse 2004).   
 
ß-Catenin in Uveal Melanoma 
Many cancers, including a large number of human melanoma cases, have shown 
to involve unregulated activity of ß-Catenin (Widlund et al. 2002). Studies show that ß-
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Catenin behavior varies depending on the tissue type (Chien et al. 2008). Accumulation 
of ß-Catenin in either the cytoplasm or nucleus has been observed during melanoma 
progression; but, whereas metastatic melanoma cells rely on the transcriptional role of ß-
Catenin for survival purposes, primary and benign cells are not as dependent (Sinnberg et 
al. 2011). An in vitro study by Guo et al. (2012) on mature mouse melanocytes used Wnt-
3a, a stimulator of the Wnt/ß-Catenin pathway and thus ß-Catenin accumulation, and 
found that it reduced the population of cells in the S phase and increased the number of 
cells in the G1 phase of the cell cycle. This demonstrated that increased Wnt/ß-Catenin 
signaling prevented cell proliferation by strictly controlling cell division (Guo et al. 
2012). Similarly, in vivo studies also show that in a melanoblast population, ß-Catenin 
stabilization may actually reduce the cell proliferation (Delmas et al. 2007). In contrast, 
other in vivo studies on melanoma cell lines suggest that ß-Catenin stabilization may lead 
to malignancy, and thus increased cell proliferation (Delmas 2007).  
 The effects of ß-Catenin in melanoma appear to vary depending on the cell type 
considered, which may insinuate patterns between ß-Catenin and survival in UM. Most 
UM cell lines do not carry genetic mutations of the ß-Catenin protein, which insists 
investigation on a possible post-translational mechanism through which its expression 
increases (Edmunds et al. 2002; Zuidervaart et al. 2007). A number of in vitro studies 
have utilized protein factors to study ß-Catenin expression and observe its upregulation 
through post-translational means, such as inhibition of its degradation (Zuidervaart et al. 
2007). Although in vitro studies on melanoma cells indicate cell proliferation due to ß-
Catenin accumulation, Kim et al. (2010) showed that overexpression of ß-Catenin in a 
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particular UM cell line can prompt apoptosis and restrict their proliferation. Ye et al. 
(2008) employed hepatocyte growth factor, which promotes UM cell migration, and 
observed a dose-dependent downregulation of ß-Catenin without nuclear translocation, 
suggesting that metastasis does not rely heavily on nuclear levels of ß-Catenin; at the 
same time, however, it has also been suggested that cytoplasmic ß-Catenin may behave 
as the trigger for cell migration (Zuidervaart et al. 2007). This discrepancy highlights the 
importance of compartmentalization of ß-Catenin within the cell. A clinical study by 
Zuidervaart et al. (2007) on UM patients noted a significant increase in Wnt ligand and 
thus Wnt/ß-Catenin signaling in primary tumors of patients with poor prognosis. 
Activation of the Wnt/ß-Catenin pathway and subsequent increases in ß-Catenin levels 
are believed to correlate with shorter survival time for UM patients (Zuidervaart et al. 
2007). These dissimilar effects of ß-Catenin expression in melanoma may be due to 
variations in how ß-Catenin interacts with other proteins in a cell (Zuidervaart et al. 
2007). Nonetheless, the distinct functions of ß-Catenin in different cells or tissues suggest 
that examination of ß-Catenin expression and Wnt/ß-Catenin signaling in individually 
isolated tumor specimens could help predict survival chances (Zuidervaart et al. 2007). 
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Figure 2: Wnt/ß-Catenin Signaling Pathway (Canonical (beta-Catenin-Dependent) 
Wnt Signaling Image). This figure provides a simple representation of the currently 
accepted model of the Wnt/ß-Catenin signaling pathway. In the “off “ state, there is no 
Wnt ligand bound to the frizzled receptor, and so any cytoplasmic ß-Catenin is degraded 
by the APC-Axin-CKI-GSK-3 complex. The TLE/Groucho co-repressors bind TCF/LEF 
and trigger their functions as repressors of gene transcription. When Wnt ligands bind 
frizzled, the signaling cascade is activated and in the “on” state. Consequently, ß-Catenin 
accumulates in the cytoplasm, translocates to the nucleus, and binds TCF/LEF to trigger 
their functions as promoters of gene transcription. This can lead to aberrant cell growth 
and cancer.  
This image is downloaded and adapted from Sino Biological Inc. (www.sinobiological 
.com). 
 
 
	  13	  	  
Specific Aims 
 Although UM represents a small percentage of all melanomas, UM has a high risk 
of liver metastasis and subsequently, death (Bedikian 1995; Buder et al. 2013). 
Development of UM may be due to a variety of genetic mutations, constitutive activation 
of signaling pathways, or irregular associations among molecular factors responsible for 
regulating cellular functions. This complicates the search for successful therapies because 
each melanocyte cell can transform into a distinct malignant cell line through unique 
modifications and interactions. Further, findings suggest that UM tumors can be 
composed of more than one type of malignant UM cell line (Patel et al. 2011). Thus, 
depending on the root source of the malignancy and specific cell lines involved, treatment 
options may vary.    
 Our study focuses on investigating the activity of PKC and its influence on the 
Wnt/ß-Catenin pathway. PKC and ß-Catenin were selected as targets to inhibit in two 
GNAQmt UM cell lines, MEL202 and OMM1.3. Inhibition of these pathway points was 
accomplished using cardamonin (CD), a Wnt/ß-Catenin inhibitor, FH535 (FH), a ß-
Catenin/TCF inhibitor, and bisindolylmaleimide I (BIM), a highly specific PKC inhibitor, 
in a dose-dependent manner. Activity of ß-Catenin was investigated further in depth with 
Wnt-3a ligand to comprehend the effects of stimulating the Wnt/ß-Catenin pathway. In 
addition, western blotting, siRNA transfection, reverse phase protein array (RPPA), and 
reverse transcription polymerase chain reaction (RT-PCR) were used to justify our 
claims. Previous studies have shown that combination therapies aiming to inhibit activity 
of more than one pathway or their respective molecular components are more effective in 
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controlling cell growth and development of cancer, and so relationships between these 
distinct protein molecules were sought (Khalili et al. 2012). 
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METHODS  
Cell Culture 
 The genotype of MEL202 and OMM1.3 (GNAQmt, GNA11wt, and BRAFwt) UM 
cell lines has been reported (Van Raamsdonk et al. 2008; Mitsiades et al. 2011; Griewank 
et al. 2012). All cell lines used were confirmed by Sanger sequencing to harbor the 
genotypes described above and were passaged for fewer than 6 months afterwards. All 
cells were grown in filtered DMEM/F12 (Invitrogen, Carlsbad, CA) with 100 units/ml 
penicillin, 100 µg/ml streptomycin, 10% FBS (Invitrogen), 1% MEM vitamin solution 
(Gibco, Gaithersburg, MD), and 1% MEM non-essential amino acids (Gibco).  
 
Reagents 
 The Wnt/ß-Catenin inhibitor, CD, the ß-Catenin/TCF inhibitor, FH, PKC 
inhibitor, BIM, and human recombinant Wnt-3a were purchased from R&D Systems, 
(Minneapolis, MN), and reconstituted in DMSO (Sigma-Aldrich, St. Louis, MO) 
according to the manufacturers instructions. ß-Catenin antisense oligonucleotides were 
purchased from Invitrogen. Antibodies for ß-Catenin, ß-actin, the phosphorylated form of 
AKT, Erk1/2, and LC3BII were purchased from Cell Signaling (Danvers, MA).   
 
Treatment with Inhibitors 
  Dose response curves were created for each cell line with each inhibitor under 
sterile conditions. Prior to treatment with the various reagents, cells were plated in 24-
well cell culture plates with 5,000 cells per well in a volume of 500 µL media. The plated 
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cells were incubated for a minimum of 24 hours to ensure adherence. All treatments, 
including controls, were performed using a total volume of 400 µL of media.  Cells were 
treated with CD alone at concentrations of 0 µM, .5 µM, 3 µM, 10 µM, and 30 µM. 
Treatment with FH alone was conducted at concentrations of 0 µM, .05 µM, .1 µM, .3 
µM, 1 µM, and 10 µM. Each treatment condition for CD and FH was repeated in four 
separate wells. After treatment with the inhibitors, cells were incubated for 72 hours, after 
which MTT assays were performed.  
 
Treatment with Wnt-3a 
 Dose response curves were created for each cell line with different concentrations 
of Wnt-3a under sterile conditions. Five thousand cells were plated 24 hours prior to 
treatment to ensure adherence. Treatments with Wnt-3a alone were conducted at 
concentrations of 0 ng/mL, 100 ng/mL, 200 ng/mL, and 300 ng/mL. Following the 
addition of Wnt-3a, the treatment conditions were replenished after 96 hours. MTT 
assays were done 168 hours after the initial treatment. 
 
MTT Assay 
 MTT assays were performed to determine the effect of the inhibitors and 
activators on cell viability. MTT solution was made using 1 mg of Molecular Probes® 
MTT reagent per 2 mL of sterile phosphate buffered saline. After ensuring the solution 
was completely dissolved, the cells were incubated with the MTT solution at 37°C with 
5% CO2 for four hours. The formazan crystals were dissolved with a 1:1 ratio mixture of 
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DMSO and isopropanol (Sigma-Aldrich) that was added to each well. Complete 
dissolution and homogeneity were ensured by keeping the plates on a vigorous shaker for 
about 20 minutes. Softmax® Pro Data Acquisition and Analysis Software was used to 
read the absorbance of the samples at a wavelength of 570 nm.  
 
Western Blotting 
 1x106 cells from both cell lines, MEL202 and OMM1.3, were plated and treated 
with BIM at concentrations of 0 µM, 5 µM, 10 µM, and 20 µM. After 48 hours of 
incubation under these treatment conditions, western blots were performed after 
collecting, centrifuging, and lysing the cells in a solution of 50 mM Tris-HCl with 120 
mM NaCl, 1% Igepal, and proteinase inhibitors from Complete™ (Indianapolis, IN). 
After collecting the protein lysates, 30 µg of protein was loaded into each well in a 12% 
sodium dodecyl sulfate-polyacrylamide membrane to perform gel electrophoresis. The 
proteins were then electroblotted onto nitrocellulose sheets and incubated in blocking 
buffer (20% IgG-free horse serum and PBS) for one hour. The respective primary 
antibodies (1:1000) were added to the membrane-bound proteins and incubated overnight 
at 4°C. Dilute (1:10,000) respective secondary antibodies were added to the membrane 
after washing with PBS. All the membranes were subsequently stripped of the primary 
and secondary antibodies and incubated with the anti-ß-actin Clone AC-15 mouse 
monoclonal antibody (Sigma-Aldrich) for normalization. Enhanced chemiluminescence 
(ECL kit, Pierce Chemical, Rockford, IL) was used to detect the proteins. 
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siRNA Transfection 
 siRNA silencing of ß-Catenin (siCTNNB1) was used to interpret the influence of 
ß-Catenin gene knockdown alone and in combination with BIM on MEL202 cell 
viability. Cells were plated in two 24-well plates and incubated for 24 hours to ensure 
adherence. After, a mixture of siRNA and Lipofectamine™ RNAiMAX (Invitrogen) was 
made in OptiMEM I Reduced Serum Medium (Invitrogen). The Lipofectamine was used 
to transfect the cells with 30 nM Stealth RNAi™ siRNA Duplex Oligoribonucleotides 
(Invitrogen) as directed by the manufacturing company. Cells were treated with either 
control or siCTNNB1 oligonucleotides alone, 1 µM or 2 µM BIM alone, or their 
combinations. MTT cell viability assay was performed 6 days after the initial treatment to 
assess the effects of the treatment conditions and statistical analyses of data were done 
after subtracting absorbance values obtained at 630 nm from values obtained at 570 nm. 
 
Reverse Phase Protein Array (RPPA) 
 After treatment with 20 µM BIM, MEL202 cellular protein expression was 
analyzed. Cells were incubated for 6, 24, or 48 hours after initial treatment. Each 
treatment condition had its particular set of controls with DMSO. Nitrocellulose-coated 
slides were used to arrange and probe the cell lysates with antibodies. 
Diaminobenzidamine (DAB) colorimetric reaction was used to visualize the proteins, 
upon which the proteins were scanned and their image density was evaluated 
numerically.  
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Reverse Transcription Polymerase Chain Reaction (RT-PCR) 	   After	  treatment	  with	  20 µM BIM, MEL202 ß-Catenin mRNA production was 
analyzed. Cells were incubated for 6 or 24 hours, after which absolute quantities of 
mRNA transcripts were retrieved. Primers were purchased from Sigma-Aldrich and 
probes were purchased from Roche Universal Probe Library (Indianapolis, IN). Cellular 
content of mRNA was separated using a Qiagen RNeasy kit (Qiagen, Valencia, CA) and 
the company’s recommended instructions. TaqMan® RNA-to-CT™ 1-Step Kit (Foster 
City, CA) and a StepOne™ PLUS Real-Time polymerase chain reaction (PCR) from 
Applied Biosystems were used to perform reverse transcription and PCR.  
 
Statistical Analysis 
 Since each well in the treated 24-well plates was represented by two separate 
wells in the 96-well plates, two absorbance values were obtained for each trial of 
different treatment conditions. To assess cell viability after treatment with any one 
reagent, the mean of the two measurements were calculated and used to compute the 
standard deviations. The effects of each treatment were interpreted by performing 
independent (unpaired) samples t-test analyses. P < 0.05 was considered to be statistically 
significant. 
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RESULTS 	  	  
PKC Activity in GNAQ-Mutant Uveal Melanoma Cells 
 We have previously mentioned that Gαq-induced transformation in UM involves 
the activation of PKC. To investigate the role of PKC in UM, we utilized BIM, a highly 
specific inhibitor of PKC activity. MEL202 and OMM1.3 cells were treated with 20 µM 
BIM and cell viability was assessed with MTT assay after a 96-hour incubation (Figure 
4). These data show that BIM decreased more than 80% of the cell viability in both cell 
lines. 
 
Figure 3: PKC Inhibition Decreases Cell Viability of GNAQ-Mutant Uveal 
Melanoma Cells. Treatment with the PKC inhibitor BIM decreased the proliferation of 
UM cells by more than 80% over 96 hours. Results are presented as mean absorbance of 
the respective control ± SD. 
 
 We then proceeded to investigate the mechanism of this effect by assessing 
whether it is an apoptotic death that involves the activation of caspases (Figure 4). 
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MEL202 cells were treated with 20 µM BIM and levels of cleaved (and therefore 
activated) caspase 3 and LC3BII were assessed with western blotting. We saw that 
caspase 3 is not activated during the BIM-induced decrease in cell viability, but the 
intracellular concentration of an autophagy marker, LC3BII, was increased, which is the 
hallmark of autophagy. 
 
Figure 4: PKC Inhibition Results in Uveal Melanoma Cell Death that is Mediated 
Through Autophagy and Does Not Involve the Activation of Caspases. MEL202 cells 
were treated with 20 µM of BIM for 72 hours or DMSO. BIM-treated cells accumulate 
LC3BII, an autophagy marker, but do not cleave and therefore activate caspase 3, a 
marker of apoptosis, confirming that cell death is caspase-independent in this model. 
 
Regulation of ß-Catenin Expression Through PKC 
  Although it is known that the Wnt/ß-Catenin pathway plays a crucial role in 
melanoma pathogenesis, the precise nature of its contribution is still unclear. We 
investigated the role of the Wnt/ß-Catenin pathway in PKC-induced UM cell death by 
visualizing the levels of ß-Catenin after PKC inhibition (Figure 5). After 48 hours of 
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incubation with BIM at concentrations of 0 µM, 5 µM, 10 µM, and 20 µM, western blots 
were performed with ß-actin as the loading control. Expression of ß-Catenin was found to 
increase, more significantly in the OMM1.3 cell line, as the concentration of BIM was 
increased. RPPA technology was also used to evaluate the increase in ß-Catenin protein 
expression in MEL202 cells after PKC inhibition (Figure 6). RPPA results show that 
compared to the control treatment with DMSO, treatment of MEL202 cells with 20 µM 
of BIM significantly increased ß-Catenin protein expression by 374.28% after 6 hours, 
454.5% after 24 hours, and 404.12% after 48 hours of incubation.   
 
Figure 5: Effect of BIM on the Protein Expression Levels of ß-Catenin, p-AKT, and 
ERK1/2. Western blots of A) MEL202 and B) OMM1.3 after 48 hours of treatment with 
BIM show an increase in ß-Catenin and p-AKT expression in a concentration-dependent 
manner. Protein expression levels of ERK1/2 did not change in response to treatment 
with BIM.   
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Figure 6: Effect of BIM on MEL202 ß-Catenin Protein Expression Levels. RPPA 
analysis of ß-Catenin protein levels after treatment with 20 µM of BIM in MEL202 cells 
was done after 6 hours, 24 hours, and 48 hours. Results show that treatment with BIM, 
regardless of incubation times, leads to an increase in the expression of ß-Catenin. 
Results are presented as mean absorbance of the respective control ± SE.    
 
 To determine if PKC inhibition amplifies ß-Catenin protein expression through 
increased transcription and subsequently translation, expression of ß-Catenin mRNA 
transcripts were determined. MEL202 and OMM1.3 cells were treated with 0 µM, 5 µM, 
10 µM, and 20 µM of BIM and incubated for 48 hours prior to RT-PCR experiments 
(Figure 7). The RT-PCR failed to show an upregulation of ß-Catenin mRNA 
transcription, but instead showed a decrease in ß-Catenin mRNA levels. Collectively, this 
data suggests showing that the mechanism of PKC-induced upregulation of ß-Catenin 
levels was post-translational.  
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Figure 7: Effect of BIM on mRNA Expression Levels of ß-Catenin. MEL202 and 
OMM1.3 cells were treated with the indicated concentrations of BIM for 48 hours, 
mRNA was isolated, and RT-PCR was performed. Treatment with BIM decreased 
mRNA levels in a dose-dependent fashion in A) MEL202 and B) OMM1.3. Results are 
presented as mean ± SD.  
 
PKC Inhibition Increases the Phosphorylation of AKT 
 In an effort to investigate the mechanism of BIM-induced increases in ß-Catenin 
levels, we studied the involvement of kinases, such as AKT and ERK1/2, that are known 
to modify ß-Catenin post-translationally (Figure 5). Cells were incubated with 0 µM, 5 
µM, 10 µM, and 20 µM of BIM for 48 hours and immunoblotted for the phosphorylated 
(and therefore activated) form of AKT and ERK1/2. Treatment with BIM increased the 
phosphorylated form of AKT (p-AKT) but did not affect ERK1/2, pointing to the role of 
AKT in the increase of ß-Catenin levels. 
β-Catenin Inhibition Has Dose-Dependent Effects on GNAQ-Mutant Uveal 
Melanoma Cells 
 To assess the effects of inhibiting components of the Wnt/β-Catenin signaling 
pathway on cell proliferation, cells were treated with CD, a Wnt/ß-Catenin inhibitor, and 
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FH, a ß-Catenin/TCF inhibitor, separately at various concentrations. After 36 hours, MTT 
cell viability assays showed that low doses of CD (.5 µM and 3 µM) increased cell 
proliferation while higher concentrations of CD (10 µM and 30 µM) inhibited cell 
proliferation in both, MEL202 and OMM1.3 (Figure 9). In comparison to the control 
cells, average growth of MEL202 cells after treatment with .5 µM and 3 µM of CD 
increased by 15.84% and 10.99%, respectively. At 10 µM and 30 µM of CD cell growth 
was reduced by 32.57% and 57.23%, respectively. Similarly, treatment with .5 µM and 3 
µM of CD led to an increase in OMM1.3 cell proliferation of 71.8% and 12.73%. After 
treatment with 10 µM and 30 µM of CD, cell proliferation was reduced by 73.73% and 
78.05%, respectively.  
 Results were similar with the inhibitor FH that increased cell proliferation at low 
levels but inhibited cell proliferation at higher levels (10µM) in both, MEL202 and 
OMM1.3 (Figure 10). In comparison to the control cells, average growth of MEL202 
cells after treatment with .05 µM, .1 µM, .3 µM, and 1 µM of FH was increased by 
10.45%, 10.94%, 14.22%, and 12.88%, respectively. Treatment with 10 µM of FH 
significantly reduced cell growth by 53.22%. Likewise, after treatment with .05 µM, .1 
µM, .3 µM, and 1 µM of FH, OMM1.3 cells further proliferated by 24.53%, 57.63%, 
122.68%, and 6.35%, respectively. Contrastingly, 10 µM of FH reduced cell proliferation 
by 75.59%. 
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Figure 8: Treatment with Cardamonin Increased Proliferation at Low Levels and 
Decreased It at High Levels. The effect of cardamonin on the proliferation of MEL202 
and OMM1.3 cells is concentration-dependent, with P < 0.05 considered significant. 
After 36 hours of incubation with CD at various concentrations, MTT results indicate that 
at .5 µM and 3 µM, cell proliferation increases while at 10 µM and 30 µM, CD causes a 
significant decrease in cell growth compared to the control cells. Results are presented as 
mean ± SE of four trials. *Significant values for only MEL202. **Significant values for 
MEL202 and OMM1.3.  
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Figure 9: Treatment with FH535 Increased Proliferation at Low Levels and 
Decreased It at High Levels. The effect of FH535 on the proliferation of MEL202 and 
OMM1.3 cells is concentration-dependent, with P < 0.05 considered significant. After 36 
hours of incubation with FH at various concentrations, MTT results indicate that FH 
increases cell growth, but a higher dose of FH (10 µM) significantly decreases cell 
growth in comparison to the control cells. Results are presented as mean ± SE of four 
trials. *Significant values for only MEL202. **Significant values for MEL202 and 
OMM1.3. 
 
Specific Knockdown of ß-Catenin Increases UM Cell Proliferation 
 Our results from the Wnt/ß-Catenin inhibitors effect on UM cell proliferation and 
viability were further solidified with treatment with ß-Catenin antisense oligonucleotides 
that target only ß-Catenin and do not have the non-specific side effects of small molecule 
inhibitors (Figure 10). 
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Figure 10: Treatment with ß-Catenin Antisense Oligonucleotides Increased 
Proliferation in MEL202 Cells. ß-Catenin knockdown in MEL202 increases cell growth 
in two distinct trials. Results are presented as % increase in proliferation in relation to the 
respective control ±	  SD.	   
 
Activation of Wnt/ß-Catenin Pathway with Wnt Treatment Decreases Uveal 
Melanoma Cell Proliferation 
 To further confirm the pro-survival effect of ß-Catenin inhibition on UM cells, we 
studied the effect of Wnt-3a, a natural activator of the pathway. Stimulation of the Wnt/ß-
Catenin with recombinant human Wnt-3a was found to have a dose-dependent effect on 
UM cell proliferation by significantly inhibiting cell proliferation at high concentrations 
in both, MEL202 and OMM1.3 lines (Figure 11). The effect of Wnt-3a was dependent on 
the cell line with mild proliferating effect on OMM1.3 in lower doses (33.11% for the 
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200 ng/mL dose). Wnt-3a treatment resulted in significant decrease in cell proliferation 
that was reduced 37.78% after treatment with 300 ng/mL of Wnt-3a in MEL202 and 
55.27% in OMM1.3. 
 
Figure 11: Wnt/ß-Catenin Decreases Uveal Melanoma Cell Proliferation. After 168 
hours of incubation with Wnt-3a at various concentrations, MTT results indicate that 
Wnt-3a decreases cell viability at 300 ng/mL in both cell lines compared to the control 
cells. Results are presented as mean ± SE. *Significant values for only OMM1.3. 
**Significant values for MEL202 and OMM1.3. 
 
ß-Catenin Mediates BIM-Induced Cell Death 	   Based	  on	  the	  data	  that	  ß-­‐Catenin	  downregulation	  has	  a	  prosurvival	  effect	  on	  UM	  cells,	  we	  investigated	  whether	  ß-­‐Catenin	  mediates	  the	  cell	  death	  induced	  upon	  PKC	  inhibition	  (Figure	  12	  and	  13).	  The	  results	  show	  that	  compared	  to	  the	  controls,	  treatment	  with	  only	  1	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  BIM	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  proliferation	  by	  35.36%.	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treatment	  with	  only	  1	  μM	  BIM,	  combination	  treatment	  with	  siCTNNB1	  and	  BIM	  increased	  cell viability by 69.41% and 132.89%.  	   MTT	  assays	  from	  another	  experiment	  showed	  similar	  results.	  Compared	  to	  the	  controls,	  treatment	  with	  only	  2	  μM	  BIM	  led	  to	  a	  58.86%	  decrease	  in	  cell	  viability.	  Compared	  to	  treatment	  with	  2	  μM	  BIM	  alone,	  combination	  treatment	  with	  siCTNNB1	  and	  BIM	  increased	  cell	  proliferation	  by	  23.86%	  and	  126.14%.	  	  
	  
Figure 12: Effect of ß-Catenin siRNA and BIM on MEL202 Cell Viability. MTT cell 
viability assays show that treatment of siCTNNB1 increases cell growth and combination 
treatment with siCTNNB1 and 1 µM BIM increases cell growth when compared to 
treatment with BIM alone. Results are presented as mean % increase in cell proliferation 
in relation to the respective control ± SD.  	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Figure 13: Effect of ß-Catenin siRNA and BIM on MEL202 Cell Viability. MTT cell 
viability assays show that treatment of siCTNNB1 increases cell growth and combination 
treatment with siCTNNB1 and 2 µM BIM increases cell growth when compared to 
treatment with BIM alone. Results are presented as mean % increase in cell proliferation 
in relation to the respective control ± SD.  
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DISCUSSION 	  
 Uveal melanoma (UM) is the most common intraocular malignancy in adults and 
despite successful local control, leads to substantial mortality due to early metastasis. 
Thus, there is an unmet need for novel anticancer agents with activity against UM. The 
discovery that 50-70% of cutaneous melanomas carry mutations in the BRAF gene that 
cause constitutive activation of the MEK/ERK pathway and increased cell proliferation 
led to the development of specific B-Raf kinase inhibitors, such as PLX4032, that 
revolutionized the clinical treatment of metastatic cutaneous melanoma (Colombino et al. 
2012; Heakal et al. 2011). However, BRAF mutations are quite rare in UM. Instead, an 
equivalent oncogenic effect present in 80% of UMs is in the form of mutually exclusive 
somatic mutations in GNAQ or GNA11, which abolish GTPase activity, resulting in a 
constitutively active Gα protein (Onken et al. 2008; Van Raamsdonk et al. 2008; Van 
Raamsdonk et al. 2010; Lamba et al. 2009; Dratviman-Storobinsky et al. 2010; Wu et al. 
2012). Mutated Gα subunits lead to constitutive activity of the MAPK/ERK signal 
transduction pathway and subsequently, melanocyte transformation, and so have been 
considered an early event in the progression of UM (Wu et al. 2012; Jovanovic et al. 
2013). Distinct sensitivity patterns of UMs to targeted therapies have been identified and 
Gαq-induced signaling has been established as the oncogenic driver in Gαq-mutant UM 
cells via a pathway involving PKC (Mitsiades et al. 2011). Dissection of the signaling 
pathway downstream of GNAQmt highlighted the role of PKC signaling in UM. We have 
found that pharmacological inhibition of Gαq or PKC exerts anticancer activity in 
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GNAQmt UM that involves autophagy and represents a novel treatment paradigm for 
cancer. We proceeded to investigate the role of β-Catenin in UM and its crosstalk with 
the GNAQ/PKC pathway. 
 
PKC Role in GNAQ-Mutant Cells 
 We have found that the PKC inhibitor BIM has profound effects on several 
GNAQmt UM cell lines. Our data highlight the role of the PKC pathway in GNAQmt UM 
cell proliferation and survival. It is known that transfection of GNAQmt into NIH-3T3 
cells activates PLCβ that catalyzes the hydrolysis PIP2 into inositol and triggers Ca2+ 
release and DAG which activates PKC (Wu et al. 1992). We have previously found that 
RNAi-mediated silencing of GNAQ suppresses PKC activity via depletion of DAG. In 
detail, we demonstrated that when GNAQmt UM cells were transfected with siRNAs for 
GNAQ or various forms of PKC in the presence of increasing concentrations of the 
phorbol ester PMA that mimicks the effects of DAG, PMA could rescue the viability of 
cells transfected with GNAQ siRNA but not of cells transfected with PKC siRNA (data 
not shown). Therefore, Gαq operated upstream while PKC operated downstream of DAG 
in GNAQmt UM. By utilizing RNAi screening experiments, we previously identified 
PKCα as the key mediator of growth signaling and MEK/ERK activation downstream in 
the signaling cascade of the mutated GNAQ protein in Mel202 cells (data not shown). 
These data provide proof of concept that GNAQmt induced signaling can be selectively 
targeted in melanoma and support a role for PKC in this oncogenic pathway. Nearly half 
of all UM cases carry somatic mutations in the GNAQ gene, which can lead to aberrant 
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signaling of the MAPK/ERK pathway and cell proliferation (Jovanovic et al. 2013). A 
potent upstream regulator of the MAPK/ERK pathway is PKC, which has been shown to 
be upregulated in many malignancies (Wu et al. 2012). RNAi-mediated silencing of 
GNAQ suppressed phosphorylation of the MEK and ERK1/2 kinases according to our 
previous data. In an effort to identify potential links between the PKC and MEK/ERK 
pathway, we investigated the phosphorylation of Raf kinase inhibitor protein (RKIP). 
RKIP in its dephosphorylated state is an inhibitor of the Raf/ERK pathway, and upon 
PKC-dependent phosphorylation can be inactivated, thus releasing the activity of the 
Raf/MEK/ERK pathway. Therefore, PKC is not only a mediator of the Gαq pathway but 
can also, through phosphorylation and inactivation of RKIP, activate the Raf/MEK/ERK 
pathway. This could be a link between the Gαq/PKC pathway and ERK activation. 
  The PKC inhibition-mediated cell death in our experiments does not appear to 
involve the activation of caspases (in particular caspase 3), which is the hallmark of 
apoptosis, but it involves the translocation of LC3BII into the phagosomes that 
characterizes autophagy, a form of programmed cell death involving the collaboration of 
autophagosomes and lysosomes (Wolf et al. 1999; Mizushima et al. 2010). 
Autophagosomes incorporate a protein complex that requires LC3BII, and so the amount 
of this protein observed within a cell is proportional to the number of functional 
autophagosomes (Mizushima et al. 2010). We have also previously found that PKC 
inhibition-mediated cell death – similar to GNAQ downregulation-mediated cell death- is 
preceded by an early suppression in mitochondrial respiration, as evidenced by decreased 
oxygen consumption rate, which occurred while the mitochondrial membrane potential 
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was still intact (data not shown). Therefore, the decrease in mitochondrial respiration was 
not a non-specific sequel of the cell’s demise but an early result of the PKC inhibition. 
Several published articles show that PKC isoforms such as PKCα regulate mitochondrial 
function. Translocation of PKCα to the mitochondria occurs with several toxic stimuli 
such as ischemia following reperfusion, heat shock, and chemotherapeutic agents 
(Fernández et al.; Wang et al. 2007). This translocation involves targeting PKCα to the 
inner mitochondrial membrane by PICK1 (protein interacting with protein kinase C) and 
confers resistance to cell death from drug-induced apoptosis (Wang et al. 2003). This 
effect involves the PKCα-mediated phosphorylation of BCl2 (B-cell lymphoma 2) on 
Ser70 and decreased dimerization of the pro-apoptotic protein BAX that promotes cell 
survival (Wu et al. 2002; Ruvolo et al. 1998). As seen in our model, PKCα inhibition in 
glioma cells collapses mitochondrial membrane potential, decreases complex I and 
pyruvate dehydrogenase activities, and increases mitochondrial ROS (reactive oxygen 
species) production (Wang et al. 2006). Singh et al. (2012) have also found that PKC 
inhibition induces autophagy and induction of cytoplasmic vacuolations with conversion 
of microtubule associated protein LC3-I to LC3-II as observed in our model that involves 
the inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells.  
 
PKC-Mediated Increase in ß-Catenin Protein Levels 
 Our data show that PKC inhibition results in increased ß-Catenin protein but not 
mRNA levels, pointing to the fact that this regulation is post-translational. Intracellular ß-
Catenin levels in the cytoplasm are tightly regulated by multiple pathways. In the GSK-3-
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dependent pathway, ß-Catenin is phosphorylated at serine residues and associates with a 
destruction complex containing GSK-3/APC/Axin that targets it for proteasomal 
degradation (Cadigan 2008; MacDonald et al. 2009). In the Siah-1 pathway, Siah 
interacts with APC and recruits the ubiquitinilation of ß-Catenin, independent of GSK-3 
(Liu et al. 2001). Upregulation and stabilization of the protein ß-Catenin in a number of 
cancers has been validated (Logan & Nusse 2004). Mutations in the ß-Catenin, APC or 
Axin genes that promote the stabilization of ß-Catenin are found in several cancers (Giles 
et al. 2003). β-Catenin stability is also regulated by protein phosphatases like PP2A that 
can bind Axin and dephosphorylate GSK-3 substrates, promote the dissociation of GSK-3 
from the destruction complex and prevent the phosphorylation of ß-Catenin (Jonkers et 
al. 1997; Li et al. 1999). Multiple studies have investigated the role of PKC on ß-Catenin 
regulation. Orford et al. (1997) showed that PKC inhibition causes ß-Catenin 
accumulation in breast cell lines without Wnt activation, whereas Gwak et al. (2006) 
showed that PKC directly phosphorylates important residues in ß-Catenin that targets it 
for the proteasome in the presence of Ca2+ and a lipid activator. Several of the ß-Catenin 
residues that PKC is essential for GSK-3-mediated phosphorylation of its N-terminal in 
the destruction complex can bypass the need for “priming kinases” (Liu et al. 2002). PKC 
was also found to phosphorylate the ubiquitination targeting sequence on ß-Catenin to 
target it for the proteasome (Orford et al). Therefore, our findings that PKC inhibition 
results in ß-Catenin accumulation could be due to a direct effect. 
 On the other hand, BIM-induced ß-Catenin upregulation could be indirect and 
through the activity of other kinases. We found that BIM treatment results in 
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phosphorylation and therefore activation of AKT, and that treatment with AKT inhibitors 
significantly decreased the BIM-induced upregulation of ß-Catenin levels (data not 
shown). Therefore, AKT can partially be responsible for the ß-Catenin stabilization. It 
was shown that AKT-induced ß-Catenin phosphorylation dissociates it from the cell-cell 
contacts and accumulates it in the cytoplasm and the nucleus enhancing in parallel its 
transcriptional activity (Fang et al. 2007). Alternatively, p-AKT was shown to 
phosphorylate GSK-3, inhibit its activity, and disturb the degradative role of the APC-
Axin-CKI-GSK-3 protein complex (Kitagishi et al. 2012). This enables large amounts of 
ß-Catenin to accumulate in the cytoplasm and translocate into the nucleus (Cadigan 
2008). Therefore, our observed increase in ß-Catenin protein expression levels after PKC 
inhibition with BIM could be due to an increase in p-AKT expression, which in turn 
inactivates GSK-3 and hinders the breakdown of cytoplasmic ß-Catenin through indirect 
means.  
 
Wnt/ß-Catenin Pathway Role in Uveal Melanoma Survival and BIM-Induced Cell 
Death   
 The collective data from the Wnt pathway inhibitors and the ß-Catenin antisense 
experiments showed that ß-Catenin inhibition increased proliferation in GNAQmt UM 
cells. The concept that ß-Catenin inhibition is a pro-survival mechanism in UM was 
corroborated with utilization of activators of the pathway, such as Wnt-3a, that showed a 
dose-dependent decrease in cell viability. Activation of Wnt/ß-Catenin signaling typically 
leads to aberrant cell proliferation due to increased gene transcription, but our results 
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shed light on new possibilities. Experiments by Guo et al. (2012) also revealed 
concentration-dependent inhibition of cell proliferation in melan-a cells, or mouse 
melanocytes, after treatment with Wnt-3a-expressing adenovirus. In agreement, research 
by Chien et al. (2009) indicates that activation of the Wnt/ß-Catenin pathway in mouse 
melanoma B16-F1 cells using Wnt-3a leads to nuclear accumulation of ß-Catenin, which 
corresponded to a decrease in proliferation. In spite of the accepted theory that increased 
Wnt signaling can lead to cancer, we considered this conflicting phenomena to be a result 
of ß-Catenin’s involvement in some form of programmed cell death (MacDonald et al. 
2009). Interestingly, Biechele et al. (2012) have found that endogenous ß-Catenin is 
required to induce apoptosis in melanoma cells and that activation of the Wnt pathway 
strongly synergizes with BRAFmt inhibition to decrease tumor growth in vivo and 
increase cell death in vitro. In particular, they found that administration of PLX4720, an 
inhibitor of the mutated BRAF protein, synergizes with the activated Wnt pathway in 
decreasing AXIN1, the limiting component of the destruction complex, and therefore 
stabilizes ß-Catenin and induces melanoma cell death (Biechele et al. 2012). Although 
UM cells rarely carry mutations on the BRAF gene, the oncogenic driver in UM is the 
mutated Gαq protein that has a similar behavior to the mutated BRAF protein. Therefore, 
it is worthy to speculate that PKC inhibition, which behaves similar to GNAQ inhibition, 
synergizes with the activated ß-Catenin to promote cell death in UM.  
 Our data also show that BIM-induced cell death in UM is attenuated significantly 
with ß-Catenin downregulation with siRNA, further solidifying the pro-apoptotic role of 
ß-Catenin in UM and its significance in the mutant GNAQ pathway. Compelling 
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evidence for the validity of our speculation comes from Zimmerman et al. (2013), whose 
work examined different mouse and human melanoma cell lines. These melanoma cells 
generally evade cell death mediated by TNF Receptor Death-Inducing Ligand (TRAIL), 
but when they were treated with recombinant human TRAIL in conjunction with Wnt-3a 
to increase Wnt/ß-Catenin signaling, there was a significant increase in cell death 
(Zimmerman et al. 2013). Since activation of the Wnt/ß-Catenin pathway elicits ß-
Catenin accumulation in the cytoplasm, its influence on TRAIL-mediated cell death was 
studied by inhibiting its degradation, which also enhanced cell death (Zimmerman et al. 
2013). 
 Our data that ß-Catenin plays a pro-apoptotic role in UM can be corroborated 
from observations from animal models and clinical samples. Murine models for 
melanoma have demonstrated the anti-proliferative and tumor-suppressing role of Wnt/β-
Catenin signaling, which entails nuclear accumulation of β-Catenin (Chien et al. 2008). 
Recent findings that large amounts of nuclear β-Catenin are common in primary 
melanoma tumors and suggestive of improved prognosis highlight this protein’s capacity 
to help better understand the etiology of malignant melanoma (Chien et al. 2008). Large 
amounts of ß-Catenin have been linked to primary tumors compared to metastases, 
insisting that a decrease in Wnt/ß-Catenin signaling represents melanoma development 
(Chien et al. 2009). Moreover, in human melanoma cells, high levels of nuclear ß-
Catenin correspond with better prognosis and reduced tumor development (Chien et al. 
2009). Maelandsmo et al. (2003) reveal that many superficial spreading melanomas have 
high levels of cytoplasmic ß-Catenin in the preliminary stages, while those undergoing 
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metastases have lower levels. A decrease in ß-Catenin expression strongly correlates with 
malignant growth, and so this protein may be central to preventing melanoma 
progression. Analyses of tumors from melanoma patients with better prognosis also 
revealed high levels of nuclear β-Catenin, which is suspected to affect tumor 
development by communicating with the MAPK/ERK and PI3K/AKT pathways, further 
diversifying and increasing the number of its targets (Chien et al. 2008; Damsky et al. 
2011). Wnt/β-Catenin signaling may be a key regulator of melanoma metastasis that 
influences proliferation and invasiveness in a cell-dependent manner (Damsky et al. 
2011). Clinical trials persuasively demonstrate that nuclear accumulation of β-Catenin 
can be used as a prognostic tool, but predictions regarding survival depend on the context 
of the melanoma (Maelandsmo et al. 2003). 
 
Conclusion 
 In summary, we have established the role of PKC and ß-Catenin in GNAQmt UM. 
We found that PKC inhibition results in autophagy-mediated cell death that involves the 
stabilization of ß-Catenin by p-Akt in the cytoplasm. Results from other studies support 
our claims that increased activation of the Wnt/ß-Catenin pathway and hence, 
intracellular levels of ß-Catenin promote cell death. Examination of β-Catenin 
localization can potentially be advantageous in clinic to determine a patient’s survival 
probability, but it is crucial first to fully comprehend how this protein functions in 
different cell types. Further research on regulating β-Catenin accumulation in the nucleus 
may also pave the way for targeted therapy.
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Proposed Mechanism for BIM-Mediated Upregulation of β-Catenin and Cell Death. 
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